Skip to main content
. 2020 Jun 26;9(2):94–100. doi: 10.4103/jrpp.JRPP_19_57

Table 1.

Demographic and clinical baseline characteristics of patients

Parameters Octreotide group (n=58) Placebo group (n=58) P**
Age 54.63±1.85 55.72±1.59 0.34
Gender (male/female) 38/20 38/20 >0.5
Hb at admission (g/dL) 10.99±3.49 11.04±3.1 0.5
Systolic BP (mmHg) 114.08±14.54 112.65±13.28 0.13
Alcohol abuse, n (%) 2 (3.4) 4 (6.9) 0.34
Smocking, n (%) 8 (13.8) 14 (24.1) 0.11
NSAID, n (%) 23 (39.65) 15 (25.86) >0.5
Aspirin, n (%) 20 (34.48) 19 (32.75) >0.5
Helicobacter pylori (Pathology positive), n (%) 32 (55.17) 39 (62.24) 0.12
Reason of GI bleeding 0.98
 GU 21 (36.2) 20 (34.5)
 DU 26 (44.8) 27 (46.6)
 Esophagitis 4 (6.9) 4 (6.9)
 MWT 4 (6.9) 3 (5.2)
 EG/ED 5 (8.6) 2 (3.4)
Classification of patients based on Rockall, Blatchford, and AIMS65 scores
 Rockall score 0.12
  ≤2 25 (43.1) 38 (65.51)
  3-7 32 (55.17) 20 (34.48)
  ≥8 1 (1.72) 0
 Blatchford score 0.61
  0 9 (15.51) 6 (10.34)
  1-5 15 (25.86) 21 (36.20)
  ≥6 33 (56.89) 31 (53.44)
 AIMS65 score 0.75
  ≤2 58 (100) 56 (96.55)
  >2 0 2 (3.44)

**Spearman’s statistical test. Hb=Hemoglobin, BP=Blood pressure, NSAID=Nonsteroidal anti-inflammatory drug, MWT=Mallory-Weiss tear, EG/ED=Erosive gastritis/Erosive doudenitis, GI=Gastrointestinal, GU=Gastric ulcer, DU=Duodenal ulcer